Evidence map›Paper›PMID 30013645›Full record

ArticleOncology letters2018

Follow-up study of HPV58 variants in women with incident HPV58 infection from a Colombian cohort.

Mónica Molano, Oscar Buitrago, Pablo Moreno-Acosta, Suzanne M Garland, Nicolás Morales, Antonio Huertas, Teresa Martinez, Oscar Gamboa, Sepehr N Tabrizi, Alyssa Cornall and 1 more

Abstract read
In one paragraph

Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mónica MolanoResearch Group in Cancer Biology, National Cancer Institute, Bogotá 11001000, Colombia.
Oscar BuitragoResearch Group in Cancer Biology, National Cancer Institute, Bogotá 11001000, Colombia.
Pablo Moreno-AcostaResearch Group in Cancer Biology, National Cancer Institute, Bogotá 11001000, Colombia.
Suzanne M GarlandDepartment of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville, Victoria 3052, Australia.
Nicolás MoralesResearch Group in Cancer Biology, National Cancer Institute, Bogotá 11001000, Colombia.
Antonio HuertasResearch Group in Cancer Biology, National Cancer Institute, Bogotá 11001000, Colombia.
Teresa MartinezEpidemiologic Research Group, National Cancer Institute, Bogotá 11001000, Colombia.
Oscar GamboaUnit of Analysis, National Cancer Institute, Bogotá 11001000, Colombia.
Sepehr N TabriziDepartment of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville, Victoria 3052, Australia.
Alyssa CornallMurdoch Children's Research Institute, Parkville, Victoria 3052, Australia.
Nubia MuñozResearch Area, National Cancer Institute, Bogotá 11001000, Colombia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Certain variants of human papillomavirus (HPV)type 58 are associated with an increased risk of high grade squamous intraepithelial lesions and cervical cancer. However, little is known about the persistence of HPV58 E6/E7 variants in women with incident HPV58 infections. The aim of the present study was to evaluate the presence and persistence of HPV58 E6/E7 variants in 71 women with incident HPV58 infection throughout their follow-up. These women belonged to a cohort examined in a longitudinal study of 1,610 Colombian women, who were HPV-negative and had normal baseline cytology. E6/E7 DNA regions of HPV58-positive samples were amplified and sequenced using automated direct sequencing. A total of 639 samples were analyzed from the 71 women, and 117 samples (18.3%) were HPV58-positive. HPV58 E6/E7 variants were detected in 85.5% of the samples. The T307/A694/G744/A761 variant was identified in 88% of the samples, the T307/G744 variant was identified in 9% of samples and the T187/T307/A367/G744/G793/T798/A801/T840/C852 was identified in 3% of the samples. Overall, 50% of the HPV58 infections were present after 1 year of follow-up and all infections were cleared after 7 years. Women who had first sexual intercourse at >15 years of age had a lower clearance rate than those who had sexual intercourse for the first time at ≤15 years of age [hazard ratio (HR)=0.29; 95% confidence interval (CI)=0.09-0.92]. Likewise, parous women had a higher clearance rate than nulliparous women (HR=3.43, 95% CI=1.23-9.60). There was no difference in clearance rates between HPV58 E6/E7 variants. In conclusion, HPV58 variants were not associated with persistence of the infection in this group of women.

Indexed as

follow-up studiesgenomic variationhuman papilloma viruspersistent infection

Identifiers

PMID30013645
PMCPMC6036590

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.